Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets

Oncolytic virus company Candel has bolstered its executive team with a quartet of industry veterans headlined by new CEO Paul Peter Tak, a biotech entrepreneur and GSK veteran who plans to raise venture money to accelerate development of the company’s late-stage pipeline while adding discovery programs.

Boston-based Candel Therapeutics, formerly known as Advantagene Inc., is developing two different oncolytic virus platforms with the most advanced program in Phase III testing to treat prostate cancer. ...